Invitation to "Fallen Angel" Reverse Mergers: An Alternative to the Traditional IPO
 

An Invitation from Mintz Levin  |  View online  |  Forward this email

 
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
 

 
 

Join Us —

 

"Fallen Angel" Reverse Mergers: An Alternative to the Traditional IPO

 

  The IPO market in 2016 was abysmal, especially for the life sciences sector. Annual IPO proceeds fell to the lowest level since 2003. The IPO market forecast for 2017 is uncertain.
 
  Some life sciences companies that went public during the last IPO wave ending in 2015 still have plenty of cash yet they have "hit the wall" clinically, making them "fallen angels".
 
  In this environment, the "fallen angel" reverse merger has emerged as an attractive way for many promising life sciences companies to raise capital and to go public.

 

Join the lawyers at Mintz Levin for a panel discussion about fallen angel reverse mergers as an alternative to the traditional IPO, and learn whether this important approach might be right for your company. Our panel of experts will provide the perspectives of the deal lawyer, the private company, the fallen angel, the investor, the investment banker, and the Nasdaq consultant. You will gain insights into the key issues involved in evaluating a fallen angel reverse merger strategy, negotiating a deal, smoothly completing a transaction, and being ready for life as a public company.

 

When

 

Monday, March 6, 2017

 

3:00 – 3:30 pm | Registration
3:30 – 5:00 pm | Program
5:00 – 6:00 pm | Cocktail Reception

 

Add to Calendar

Add this date
to your calendar

 
 

Where

 

Mintz Levin, Boston Office – 38A

 

One Financial Center
Boston, MA 02111

 

Get Driving Directions

Get driving
directions

 
 

Register

 
 

Register

 

Decline

 

Forward Invitation

 

 

CLE Credit

Mintz Levin is an approved CLE provider. This seminar is accredited in the following states: California (1.5 general credit) and New York (1.5 credit in the Areas of Professional Practice).

 

Speakers

 

Matt Gardella

Matthew J. Gardella
Member, Mintz Levin

 

Megan Gates

Megan N. Gates
Co-Chair, Securities & Capital Markets Practice, Mintz Levin

 

Marc Schneebaum

Marc R. Schneebaum
Senior Vice President and Chief Financial Officer, Madrigal Pharmaceuticals, Inc.

 

Pete Zorn

Pete Zorn
Chief Corporate Officer and General Counsel, Albireo Pharma, Inc.

 

TBD

Scott Morenstein
Managing Director, CAM Capital

 

Andrew Weisenfeld

Andrew J. Weisenfeld
Partner, MTS Health Partners

 

DavidDonohoe

David A. Donohoe, Jr.
Principal, Donohoe Advisory Associates

 

 

 

BostonLondonLos AngelesNew YorkSan DiegoSan FranciscoStamfordWashington

www.mintz.com

Follow Us LinkedIn Facebook Twitter YouTube

Your e-mail address is never shared with any third parties. For more information, view our Privacy Statement.

 

 

 
 

 


Cvent - Web-based Software Solutions